Enanta Pharmaceuticals ENTA
NASDAQ ENTA
$14.08 +0.06 (+0.43%)
As of: Sep 4, 2026 · 3:59 PM EDT

Enanta Pharmaceuticals (ENTA) Revenue Growth (5y) (2017 - 2026)

Analysis

Enanta Pharmaceuticals (ENTA) Revenue Growth (5y) (2017 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Enanta Pharmaceuticals 409.30 Mn 219.79 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -7.86%
Mar 31, 2026 -3.15%
Dec 31, 2025 -10.12%
Sep 30, 2025 -8.54%
Jun 30, 2025 -0.37%
Mar 31, 2025 -11.58%
Dec 31, 2024 -20.25%
Sep 30, 2024 -22.22%
Jun 30, 2024 -16.54%
Mar 31, 2024 -15.52%
Dec 31, 2023 -23.76%
Sep 30, 2023 -22.38%
Jun 30, 2023 -19.89%
Mar 31, 2023 -16.58%
Dec 31, 2022 -9.15%
Sep 30, 2022 -23.18%
Jun 30, 2022 21.00%
Mar 31, 2022 15.88%
Dec 31, 2021 21.56%
Sep 30, 2021 12.92%